TOKYO – The stocks of Japan's biopharmaceutical companies have taken a hit since U.S. President Donald Trump said, almost two weeks ago, that pharma companies have been "getting away with murder." Unlike their U.S. counterparts, Japanese stocks have not recovered from that significant broadside.
TOKYO – Sanofi K.K., the Japanese subsidiary of the French multinational, is aiming to launch more than 20 new drugs in Japan by 2020. Those drugs are expected to be mostly biologics and existing drugs tested for new indications.
TOKYO – Public backlash against the proposal and internal agreement to cut the price of anticancer drug Opdivo (nivolumab) by half continues. Japan's Ministry of Health, Labour and Welfare (MHLW) promised to work on regular biennial drug price review and said the emergency review of Opdivo price was an anomaly.
TOKYO – Public backlash against the proposal and internal agreement to cut the price of anticancer drug Opdivo (nivolumab) by half continues. Japan's Ministry of Health, Labour and Welfare (MHLW) promised to work on regular biennial drug price review and said the emergency review of Opdivo price was an anomaly.
TOKYO – New drug approvals in Japan dropped to a five-year low in 2015, according to the latest report from the PMDA. While reviews are getting faster for standard products, reviews for priority products have grown increasingly longer.
TOKYO – New drug approvals in Japan dropped to a five-year low in 2015, according to the latest report from the PMDA. While reviews are getting faster for standard products, reviews for priority products have grown increasingly longer.
